Deadline: 24-Oct-2025
The Osteosarcoma Institute’s 2025-2026 Grant Cycle is now open for Clinical Trials, Correlative Science, Preclinical/Translational, and High-Risk/High-Impact grant programs!
This initiative seeks to fund work aimed at improving outcomes and treatment options for osteosarcoma patients. The process is structured to facilitate thoughtful planning and ensure that high-quality projects move forward with clear alignment to OSI’s mission.
OSI offers multiple grant paths. Clinical trials grants support Phase I/II or Phase II studies focused on improving event-free survival. Correlative science grants help understand biological factors that influence outcomes even when trials don’t yield expected results. Preclinical/translational grants advance understanding of biological dependencies and target discovery, while high-risk/high-impact grants embrace innovative ideas without heavy preliminary data requirements.
Funding is tailored to each grant type. Clinical trials may receive up to $800,000 over two to three years. Correlative and preclinical translational research can be supported with grants ranging from $200,000 to $500,000. High-risk projects may secure between $25,000 and $125,000 for one-year explorations. OSI allows up to 10% of awarded funds for indirect costs.
OSI supports global participation—organizations and investigators from outside the U.S. are eligible provided they are recognized as charitable or nonprofit equivalents in their home countries. Applicants must hold advanced research credentials and a track record of productivity. Each institution may submit only one Letter of Intent per grant cycle.
Grant awards are confirmed by July 2026. Funding begins with an initial payment once projects are ready to launch, followed by milestone-based payments tied to regular progress reporting. Investigators are supported with in-depth feedback at each stage and are expected to contribute to publicity and dissemination of results.
This grant cycle offers a bold chance for investigators to pursue impactful osteosarcoma research across the spectrum of discovery, from laboratory innovation to patient-centered trials.
For more information, visit Osteosarcoma Institute.
